

Volume 10 Number 01 Page 932-955 June 2025 ISSN 2012 – 9238

Sri Lanka Journal of Indigenous Medicine

SLJIM



**Peer reviewed research publication of the
FACULTY OF INDIGENOUS MEDICINE
University of Colombo, Rajagiriya, Sri Lanka.**

Sri Lanka Journal of Indigenous Medicine (SLJIM)

Volume 10

Number 01

Page 932 - 955

June 2025

EDITORIAL BOARD

EDITOR-IN-CHIEF

Prof. K. R. Weerasekera PhD
Dept. of Kayachikitsa and Deshiya Chikitsa
Faculty of Indigenous Medicine, University of Colombo.
Email: kumuduwe@fim.cmb.ac.lk

EDITORIAL BOARD MEMBERS

Prof. R.D.H. Kulatunga PhD
Dept. of Kayachikitsa and Deshiya Chikitsa
Faculty of Indigenous Medicine, University of Colombo.
Email: krdhkanthi@fim.cmb.ac.lk

Prof. S. M.S. Samarakoon PhD
Dept. of Kayachikitsa and Deshiya Chikitsa
Faculty of Indigenous Medicine, University of Colombo.
Email: samarakoonsms@fim.cmb.ac.lk

Prof. S.K.M.K. Herapathdeniya MD
Dept. of Dravyaguna Vignana and Swastha Vritta
Faculty of Indigenous Medicine, University of Colombo.
Email: sajeewakmk@fim.cmb.ac.lk

Prof. H.G.S.P. Hewageegana PhD
Dept. of Kayachikitsa and Deshiya Chikitsa
Faculty of Indigenous Medicine, University of Colombo.
Email: sujathahgsp@fim.cmb.ac.lk

Prof. S.D. Hapuarachchi PhD
Dept. of Dravyaguna Vignana and Swastha Vritta
Faculty of Indigenous Medicine, University of Colombo.
Email: dr.sdhapuarachchi@fim.cmb.ac.lk

Prof. S.P. Molligoda PhD
Dept. of Maulika Siddhantha and Shareera Vignana
Faculty of Indigenous Medicine, University of Colombo.
Email: molligoda@fim.cmb.ac.lk

Prof. K.P.K.R. Karunagoda PhD
Dept. of Shalya, Shalakya and Siroga and Prasutitantra
Faculty of Indigenous Medicine, University of Colombo.
Email: kaumadi@fim.cmb.ac.lk

Prof. P.R. Waratenne PhD
Associate Professor
Dept. of Maulika Siddhantha and Shareera Vignana
Faculty of Indigenous Medicine, University of Colombo.
Email: drwaratenne@fim.cmb.ac.lk

Prof. A.P.A. Jayasiri PhD
Associate Professor
Dept. of Dravyaguna Vignana and Swastha Vritta
Faculty of Indigenous Medicine, University of Colombo.
Email: dr.apajayasiri@fim.cmb.ac.lk

Prof. M.S.M. Shiffa PhD
Dept. of Moalijat, Faculty of Indigenous Medicine, University of Colombo.
Email: drshiffa@fim.cmb.ac.lk

Prof. N. Fahamiya PhD
Dept. of Ilmul Advia, Faculty of Indigenous Medicine, University of Colombo.
Email: nfahamiya@fim.cmb.ac.lk

Prof. M.I. Manuha PhD
Dept. of Ilmul Advia, Faculty of Indigenous Medicine, University of Colombo.
Email: manuha@fim.cmb.ac.lk

Prof. M.U.Z.N. Farzana MD
Dept. of Moalijat, Faculty of Indigenous Medicine, University of Colombo.
Email: muznfarzana@fim.cmb.ac.lk

LANGUAGE EDITOR

Mr. W.M.S.P.K. Wanasinghe MPhil
Dept. of English Language Teaching, Faculty of Arts
University of Colombo.
Email: samantnl@yahoo.com

ADVISORY BOARD

Prof. Pathirage Kamal Perera PhD
Dean
Faculty of Indigenous Medicine
University of Colombo.
Email: dean@fim.cmb.ac.lk

Dr. Rammanohar Puthiyedath MD(Ayu)
Director - Amrita Centre for Advanced Research in Ayurveda,
Amrita School of Ayurveda, Clappana PO, Vallikkavu,
Kollam, Kerala, India.
Research advisor to the Indian National Science Academy, Government of
New Delhi, India. Email: rammanohar@ay.amrita.edu

Dr. Christian S. Kessler MD
Research coordinator and senior physician at Charité
Universitätsmedizin Berlin, Germany.
Email: c.kessler@immanuel

Prof. A.P.G. Amarasinghe PhD
Emeritus Professor, Faculty of Indigenous Medicine
University of Colombo.
Email: drgamarasinghe@gmail.com

Dr. Palitha Serasinghe PhD
Principal Lecturer, Assistant Director & Programme Leader
The College of Ayurveda, United Kingdom.
Email: dr.serasinghe@ntlworld.com

Prof. Gomika Udugamasooriya PhD
Department of Pharmacological & Pharmaceutical Sciences University of
Houston
Senior Member- National Academy of Inventors (NAI)
United States of America. Email: gomika@uh.edu

Prof. Priya Weerasinghe PhD
Department of Pathology and Laboratory Medicine,
The University of Texas Houston McGovern Medical School (UTHealth)
United Kingdom. Email: Priya.Weerasinghe@uth.tmc.edu

Prof. Aruna Weerasooriya PhD
Cooperative Agricultural Research Center
College of Agriculture & Human Sciences
Prairie View A&M University
United States of America.
Email: at cahs.pvamu.edu

Prof. Saiyad Shah Alam MS
Director, National Institute of Unani Medicine,
Bangalore, India. Email: shahalm1971@mail.com

Prof. Abhimanyu Kumar PhD
Director, All India Institute of Ayurveda
Director General, Central Council for Research in Ayurvedic Science
New Delhi, India.
Email: ak_ayu@yahoo.co.in

Dr. MWSJ Kumari PhD
Former Acting Director
Institute of Indigenous Medicine
Senior Lecturer
Dept. of Maulika Siddhantha and Shareera Vignana
Faculty of Indigenous Medicine, University of Colombo.
Email: Saumya@fim.cmb.ac.lk

Sri Lanka Journal of Indigenous Medicine (SLJIM)

Volume 10 Number 01 Page 932-955 June 2025

Published by

Faculty of Indigenous Medicine

University of Colombo

Rajagiriya

Sri Lanka

Tel: +94 11 2692385 / 694308

Fax: +94 11 2697175

Website: www.fim.cmb.ac.lk

Email: sljim@fim.cmb.ac.lk

Cover story

Neeramulliya

Botanical name: *Hygrophila auriculata*

Family: ACANTHACEAE

Vernacular names: **Sinhala:** *Neeramulliya, Katu ikiriya, Ikiriya;*

Sanskrit: *Gokantha, Kokilaksha;* **English:** *Marsh barbel;* **Tamil:**

Vayalchulli, Neermulli; **Hindi:** *Bhankari*

Hygrophila auriculata is a spiny herbaceous shrub that grows in marshes and on the edges of water bodies; it has numerous medicinal uses, the leaves can be eaten as a vegetable, and the flowers produce nectar that attracts bees and butterflies¹.

This is a perennial aquatic herb native to Sri Lanka and tropical Asia. Erect stem, 1.25m high, armed with axillary spines to 2-4 cm long. Leaves in whorls of six, elliptic lanceolate, acute at apex, entire margins, hispid above. Flowers 6-8 in a whorl, bracts lanceolate, corolla purple². The plant is used in cancer and tubercular fistula. Root and seeds used as tonic, for asthma and dysentery. The leaf, root and seed of this plant are traditionally used for the treatment of inflammation, jaundice, hepatic obstruction, urinary infection, oedema, gout, diabetes, bacterial infection etc.³

Phytochemically, the whole plant contains phytosterols, tannins, carbohydrates, flavonoids, terpenoids, and sterols. Phalnikar *et al.*, Analyzed the oil from the seeds and reported the presence of uronic, palmitic, stearic, oleic, and linoleic acids. Apigenin-7-O-glucuronide and apigenin-7-oglucoside were isolated from the flowers and lupeol, betulin, and stigmasterol were isolated from the plant. Alkaloids, steroids, tannins, proteins, flavonoids, carbohydrates, fats, and oils were isolated from the roots. Moreover, the leaves show the presence of alkaloids, carbohydrates, proteins, steroids, glycosides, flavonoids, tannins, phenolic compounds, fats, and oils³.

References

1. Bareke, T. & Addi, A. 2022. Quantifying nectar secretion potential of *Hygrophila auriculata* (Schum.) Heine (Acanthaceae), and *Salvia leucantha* Cav. (Lamiaceae) for honey production. *Advances in Agriculture*: 1-8.
2. Kress, W.J., De Filippis, R.A., Farr, E. & Kyi, D.Y.Y. (2003). A Checklist of the Trees, Shrubs, Herbs and Climbers of Myanmar. *Contributions from the United States National Herbarium* 45: 1-590. Smithsonian Institution.
3. Dhanalakshmi S, Harikrishnan N, Srinivasan N, Pandian P, Tanisha BA, Kumar MT, *et al.* A Perspective Overview on *Hygrophila auriculata*. *Pharmacogn J.* 2020;12(6) Phcogj.com Suppl:1748-52.

Cover story by Prof. K.P.K.R. Karunagoda

Photographed by Mr. Thusitha Jayarathne

Cover page designed by Mr. K.K.P.R.K. Kohombakanda

ISSN 2012-9238

Sri Lanka Journal of Indigenous Medicine (SLJIM)

Volume 10

Number 01

Page 932 - 955

June 2025

| Contents | Page No. |
|--|----------|
| Experimental study | |
| A comparative study of prepared <i>Bhasma</i> using different marine-originated animal materials <i>Nallaperuma D.M., Herapathdeniya S.K.M.K. and Senaviratne A.M.N.D.</i> | 932 |
| Observational study | |
| Identifying the type of impairments among children with disabilities: An observational study of the Divulapitiya Divisional Secretariat Area: <i>Weerakoon W.A.S.S., Gunawardhana R.M.R., Kaushalya H.B.D. and Fernando I.M.O.</i> | 939 |
| Cace Study | |
| Management of <i>Thusta viranam</i> (Chronic diabetes mellitus associated venous leg ulcer) by using Traditional treatment regimen: A case study <i>Shomesh V., Yameni K., Keerthika C., Kasthuri S., Soruban T. and Subaveena S.</i> | 950 |

A comparative study of prepared *Bhasma* using different marine-originated animal materials

Nallaperuma D.M.*, Herapathdeniya S.K.M.K. and Senaviratne A.M.N.D.

Abstract

Rasa shastra is a main pharmaceutical branch in Ayurveda and Mercury is the main material in *Rasa shastra*. Other than mercury, different animal resources, minerals, gems, marine originated materials and some toxic plants are also described under *Rasa shastra*. *Shankha*, *Shukthi* and *Kaparda* are some of the commonly used marine originated animal materials. These materials contain Calcium and categorized under *Sudha varga*. The objective of this study is to prepare *Shankha*, *Shukthi* and *Kaparda bhashmas* according to *Rasa shastra* and to comparatively analyze the physico-chemical parameters and to determine the Calcium content of these *Bhashmas*. Boiling and steaming method was used for the purification, and incineration was done by using the muffle furnace at 550°C. *Bhashma* standardization parameters in *Rasa Shastra*; *Rekha purnatva*, *Varitharathva*, *Uththama*, *Gatha rasathva*, *Avami*, *Anjana sadrusha sukshma* and *Dantagra na kacha kacha* were performed for all these *bhashmas*. Calcium percentage in each *bhashma* was determined by titrating with 0.1M NaOH solution using phenolphthalein as the indicator. Results revealed that all the *Bhashmas* were within the standard parameters according to classical texts. According to modern physico-chemical analysis, moisture contents of all the samples were relatively low (0.40%, 1.30%, 0.95%). Total ash contents were 99.20%, 98.50% and 98% respectively. Acid insoluble ash values (52%, 77.80%, 57%) were higher than water soluble ash values (3.80%, 2.60%, 1.65%). All the samples were having an alkaline pH value (8.2, 8.0, 8.7). The highest calcium percentage was reported from

Shukthi bhashma (99.30%) and lowest from *Kaparda bhashma* (78.40%). It can be concluded that all the *Bhashmas* were having the standard quality according to Ayurveda as well as modern physico-chemical parameters. Due to the high calcium content, *Shukthi bhashma* can be highly recommended as a nutritional supplement for Calcium deficiencies among these *Bhashmas*.

Keywords: *Bhashma*, *Kaparda*, Marine originated, *Shanka*, *Shukthi*

Introduction

Ayurveda is considered as a natural healing system and one of the oldest traditional medicine systems not only in ancient India but also in the world. Ayurveda has two main objectives as prevention of diseases and curing of diseases¹. According to Ayurveda authentic texts, there are four pillars needed to achieve these two objectives. They are called as *Vaidyadi chathushpadaya*, which consists of physician, patient, attendant and drugs². Drugs play a key role among these four pillars. Drugs from the three natural sources of herbal, mineral, metal and animal origin have been described in Ayurveda.

Rasa shastra is a branch of Ayurveda that developed along with *Bhaisajya Kalpana*^{3,4}. *Rasa shastra* started as a separate science, but it slowly merged with Ayurveda. Mercury is the main material in *Rasa shastra*⁵. Other than mercury different animal materials, minerals, gems, marine originated materials and some toxic plants are also described under *Rasa shastra*⁶. The preparations which are prepared with these materials are called as

Faculty of Indigenous Medicine, University of Colombo, Sri Lanka.

*Correspondence: Nallaperuma D.M., Faculty of Indigenous Medicine, University of Colombo, Sri Lanka.
Email: dinalimalindika1993@gmail.com

Rasaushadies and there is many processing techniques applied for the preparation of those *Rasaushadies*. They are *Shodana*, *Jarana*, *Marana* and *Amruthikarana*. *Rasa shastra* texts have mentioned the superiority of these preparations⁷. When comparing with herbal preparations, *Rasaushadies* are considered as the superior preparation due to the ability of administering a lower dose, tastelessness and high potency. Also, they can be absorbed and assimilated in the body quickly⁸. Due to these special features of *Rasaushadies*, patients can get quick relief.

Marine which is called as the ‘mother of origin of life’ is also one of the richest natural sources of minerals like Calcium (Ca), Phosphorus (P) and Iron (Fe). There are many marine originated animal parts extensively used in *Rasa shastra*⁹. Conchs (*Shankha*), oyster’s shell (*Shukthi*), and cowrie shells (*Kaparda*) are some of the commonly used marine originated animal materials¹⁰. These materials which contain calcium are categorized under the *Sudha varga* in *Rasa Shastra* authentic texts. *Shankha* or conch (*Terbinella pyrum*) which belongs to the class Mollusca of family Turbinellidae is enclosed in a very hard, dense and calcareous shell¹¹. It is a large sea snail with a long spiral shell. There are two types of *Shankha* as *Vamavartha*, *Dakshinawartha*. It has properties like cooling, detoxifying, complexion enhancing and strengthening¹². It has an acid neutralizing capacity and anti-acid action and prolonged buffering action. *Shankha* is the drug of choice for gastritis, flatulence, abdominal pain, vomiting, diarrhoea and belching¹³. *Shukthi* or oyster’s shell (*Pinctada margaritifera*) belongs to the family Ostreidae. There are two varieties as *Mukthashukthi* and *Jalashukthi*. It has a cooling effect and indicated for gastritis, gastric ulcers and duodenal ulcers¹⁴. It can be converted into two forms as *Bhashma* and *Pishti*. *Kaparda* or cowerie (*Cypraea moneta*) which belongs to the family Cypraidae is a yellow colour shell having weight of 3 to 5 grams. It is used as a powerful antacid for many stomach ailments¹⁵.

All of these materials can be subjected to different special procedures mentioned in *Rasa shastra* texts

Nallaperuma et. al., Comparative study of Bhashma

and finally converted into a fine ash like preparation which is called as *Bhashma*¹⁶. These *Bhashmas* can be introduced to the human body for different ailments, in single or as compound formulations. Especially, these *Bhashmas* can be used as a medicine in Calcium deficiencies, without getting any unwanted effects. The main objective of this study is to compare the physico-chemical parameters of *Bhashmas* prepared using different common animal originated materials such as *Shankha*, *Shukthi* and *Kaparda* and to comparatively study the calcium content of these *Bhashmas*.

Materials and Methods

Collection of the raw material

The *Shanka* (Figure 1) was collected from Jaffna beach and *Shukthi* (Figure 2) and *Kaparda* (Figure 3) were collected from Panadura beach, Sri Lanka. All the raw materials were authenticated from the Department of Ayurveda Pharmacology, Pharmaceutics and Community Medicine, Faculty of Indigenous Medicine, University of Colombo, Sri Lanka.



Fig.1: Shankha
(Conch shell)



Fig.2: Shukthi
(Oyster’s shells)



Fig.3: Kaparda (Cowrie shells)

Preparation of Shankha, Shukthi and Kaparda bhashma¹⁷

Shodhana of Shankha, Shukthi and Kaparda

Shanka, Shukthi and Kaparda were taken and crushed into small pieces separately. Then the crushed parts were washed with hot water separately. Each sample was kept in a piece of a clean cotton cloth separately and prepared them as pouches (Figure 4) and put into the *Dola yantra* containing *Kanji* (vinegar) (Figure 5). Then each sample was boiled in the *Dola yantra* for one *Yama* (3 hours). After 3 hours the materials contained in the cloth pouches were allowed to cool. Then they were again washed with luke warm water and dried properly. Finally, the purified *Shankha*, *Shukthi* and *Kaparda* were obtained and subjected to *Marana* process.



Fig.4: Pouches of the samples



Fig.5: Boiling in the *Dola yantra*

Marana of Shankha

The sample of purified *Shankha* was placed in a *Sharava* (earthen crucible) and covered it with another *Sharava* having the same size, to prepare the *Sharava Samputa yantra*. The joint between the two *Sharavas* was sealed with a mud cotton cloth layer. The *Sharava samputa yantra* was subjected to a temperature of 550°C for one hour in the muffle furnace. It was taken out and let to be self-cooled. Then the pieces were powdered in a *Kalva yantra* (mortar and pestle) and grinded it with fresh *Kumari swarasa* (aloe vera juice). Then the *Chakrikas* (pellets) were prepared and dried. These pellets were kept in the

Sharava samputa yantra (Figure 6) and again subjected to a temperature of 550°C for one hour in the muffle furnace. Then let to be self-cooled. Finally,

the sample of *Sankha bhashma* was obtained and subjected to further analysis.



Fig.6: *Sharava samputa yantra*

Marana of Shukthi and Kaparda

The sample of purified *Shukthi* was placed in a *Sharava* (earthen crucible) and covered it with another *Sharava* having the same size, to prepare the *Sharava samputa yantra*. The joint between the two *Sharavas* was sealed with a mud cotton cloth layer. The *Sharava samputa yantra* was subjected to a temperature of 550°C for one hour in the muffle furnace. It was taken out and let to be self-cooled. Then the pieces were powdered in a *Kalva yantra*. Finally, the sample of *Shukthi* (Figure 7) and *Kaparda bhashmas* (Figure 8), and *Shankha bhashma* (Figure 9) were obtained and subjected to further analysis.



Fig.7: *Shukthi bhashma*



Fig.8: *Kaparda bhashma*



Fig.9: *Shankha bhashma*

Organoleptic analysis

Color, odor, taste and texture were assed under organoleptic parameters. All three samples were examined under diffuse daylight to observe the color. A small portion of samples were placed on a dish and slowly and repeatedly inhaled the air of material to sense the odor. Samples were chewed and tasted for taste sensation. Samples were touched to detect the texture.

Physico- chemical analysis¹⁸

Moisture content, total ash value, acid insoluble ash and water soluble ash values and pH were determined under physico-chemical analysis. All the procedures were repeated in triplicate.

Determination of moisture content

Accurately weighed 2g of each *Bhashma* was taken in a previously measured moisture dish. The sample was heated in a hot air oven at 105°C till constant weight was obtained. The percentage moisture content of the sample was calculated with reference to the air-dried sample.

Determination of total ash value

Accurately weighed 2g of each *Bhashma* was taken in a previously measured silica crucible. The sample was evenly spread and ignited in a muffle furnace at 550°C for 5-6 hours till carbon free white ash was obtained. The total ash value was calculated with reference to the air-dried sample.

Determination of acid insoluble ash value

To the crucible containing the total ash, 25ml of 7% HCl was added. Then the crucible was covered with a lid and boiled gently for 5 minutes. Then the lid was rinsed with hot water and this liquid was added to the crucible. Then the solution in the crucible was filtered. Insoluble matter in the crucible was collected to an ashless filter paper (whatmann no. 42) and washed it with hot water until the filtrate became neutral. The filter paper containing the insoluble matter was transferred to the original crucible, and ignited in a muffle furnace at 450°C to a constant weight. Residue was cooled in a desiccator for 30

minutes and weighed. Acid insoluble ash value was calculated with reference to the air-dried sample.

Determination of water-soluble ash value

The above procedure was repeated with 25ml of distilled water and the weight of water insoluble ash was calculated. The weight of the insoluble matter was subtracted from the total ash to obtain the weight of water-soluble ash. Water insoluble ash value was calculated with reference to the air-dried sample.

Determination of pH value

One part of each *Bhashma* was mixed with 5 parts of distilled water and then the pH was measured using a calibrated pH meter.

Determination of Calcium content

Accurately 1.30g from *Shankha bhashma* was measured. This mass was dissolved in 50ml of 1M HCl solution in a 250 ml beaker. The contents were transferred to a 250ml volumetric flask and diluted up to the 250ml mark. Then 25ml of the above solution was taken out using a pipette and transferred to a 250ml conical flask containing 2-3 drops of phenolphthalein indicator. The burette was filled up from 0.1M NaOH solution. Finally, the 25ml of acid solution in conical flask was titrated against the NaOH solution (Figure 10) till light pink end point comes (Figure 11). The titration was repeated for 3 times and taken the average volume of NaOH that was spent. The above procedure was repeated with *Shukthi* and *Kaparda bhashmas*.¹⁹



Fig.10: Titrating against NaOH




Fig.11: Light pink end point

Results

Results of Ayurveda parameters used for *Bhashma pariksha* is mentioned in Table 1.

Table 1: Results of Ayurveda parameters used for *Bhashma pariksha*

| <i>Bhashma pariksha</i> | <i>Shankha bhashma</i> | <i>Shukthi bhashma</i> | <i>Kaparda bhashma</i> |
|--------------------------------|------------------------|------------------------|------------------------|
| <i>Rekha purnatva</i> | Completed | Completed | Completed |
| <i>Varitharathva</i> | Completed | Completed | Completed |
| <i>Uththama</i> | Completed | Completed | Completed |
| <i>Gatha rasatva</i> | Completed | Completed | Completed |
| <i>Avami</i> | Completed | Completed | Completed |
| <i>Anjana sadrusha sukshma</i> | Completed | Completed | Completed |
| <i>Danta grana kacha kacha</i> | Completed | Completed | Completed |

Results of organoleptic analysis is mentioned in Table 2.

Table 2: Results of organoleptic analysis

| | <i>Shankha bhashma</i> | <i>Shukthi bhashma</i> | <i>Kaparda bhashma</i> |
|---------|------------------------|------------------------|------------------------|
| Colour | off- white | dark white | white |
| Odor | odorless | odorless | odorless |
| Taste | characteristic | characteristic | characteristic |
| Texture | powder form | powder form | powder form |

Results of physico-chemical analysis mentioned in Table 3.

Table 3: Results of physico-chemical parameters

Results of determination of calcium percentage is shown in Table 4.

| | <i>Shankha bhashma</i> M±SD | <i>Shukthi bhashma</i> M±SD | <i>Kaparda bhashma</i> M±SD |
|---------------------------|--------------------------------|--------------------------------|--------------------------------|
| Moisture content | 0.40±0.10 % | 1.30±0.10 % | 0.95±0.10 % |
| Total ash | 99.20±0.20 % | 98.50±0.20 % | 98±0.20 % |
| Acid insoluble ash value | 52±0.30 % | 77.80±0.30 % | 57±0.30 % |
| Water insoluble ash value | 3.80±0.30 % | 2.60±0.30 % | 1.65±0.30 % |
| pH | 8.2±0.2 | 8.0±0.2 | 8.7±0.2 |

Table 4: Results of determination of calcium percentage

| | <i>Shankha bhashma</i> M±SD | <i>Shukthi bhashma</i> M±SD | <i>Kaparda bhashma</i> M±SD |
|----------|--------------------------------|--------------------------------|--------------------------------|
| Calcium% | 86.60±0.25 % | 99.30±0.25 % | 78.40±0.25 % |

Discussion

Shankha, *Shukthi* and *Kaparda* are categorized under *Sudha varga* in *Rasa shastra*. *Bhashmas* of these materials were prepared according to authentic Ayurveda *Rasa shastra* texts. Final *Bhashmas* were tested by using different conventional *Bhashma pariksha* methods. They are *Rekha purnatva*, *Varitharathva*, *Uththama*, *Gatha rasathva*, *Avami*, *Anjana sadrusha sukshma* and *Dantagra na kacha kacha*.

In this study ash values of *Shankha*, *Shukthi* and *Kaparda* were 99.20±0.20%, 98.50±0.20% and 98±0.20% respectively. Ash value is a physical method which is used in drug standardization and it gives the percentage of inorganic constituents of the sample. It can be used to determine whether the *Bhashma* preparations have undergone the proper manufacturing procedure. According to the standard, *Bhashmas* should have an ash value near to 100% because ash itself is entirely composed of inorganic materials. Acid insoluble ash value of a standard *Bhashma* preparation should be more than the water soluble ash values. In this study, all three ashes are fulfilling this standard. Moisture content can detect the percentage of water content in a sample. It reflects the shelf life of a sample. The least moisture content, the better will be the shelf life of a drug. Higher moisture content is responsible for deterioration and contamination of a drug. In this study, all the three *Bhashmas* were having very low moisture content. pH values of the three *Bhashmas* are alkaline in nature. To minimize the gastric irritation due to the alkaline nature of these *Bhashmas*, authentic texts recommended grinding these materials by using aloe vera juice before incineration (*Marana*)²⁰. The highest calcium percentage was founded in *Shukthi bhashma* (99.30±0.25%) and the lowest in *Kaparda bhashma* (78.40±0.25%).

Conclusion

All the 3 *Bhashma* preparations were according to the Ayurveda standards mentioned in authentic *Rasa shastra* textual references. Modern physico-chemical analysis proves that all the *Bhashmas* are having standard quality and purity. The results of the study concludes that maximum Calcium percentage was in *Shukthi bhashma* while least one in *Kaparda bhashma*. Therefore, in Calcium deficiencies *Shukthi bhashma* can be highly recommended as a nutritional supplement.

Conflicts of Interest

Not declared.

Acknowledgement

The authors would like to pay their gratitude to the academic and non-academic staff of Department of Ayurveda Pharmacology, Pharmaceutics and Community Medicine, Faculty of Indigenous Medicine, University of Colombo for their valuable support.

References

1. Sharma P.V., (2014). Caraka Samhita. repeat ed. Varanasi: Chaukhambha Orientalia.
2. Sharma P.V., (2014). Caraka Samhita. repeat ed. Varanasi: Chaukhambha Orientalia.
3. Kamble S., Wanjari A., Rathi B., Rajput D. (2021). Pharmaceutico - Analytical study of *Mukta shukti pishti* and *Mukta Shukti Bhasma* and Comparative Evaluation of their relative oral Bioavailability. *Journal of Phamaceutical Research*, 33(31A), pp 1-9.
4. Samant A., Joshi A.B., Gurav S., Bhandarkar A.V. (2017). Significance of Parad in Rasa Shastra – A review. *Journal of Ayurvedic and Herbal Medicine*, 3(3), pp 169-174.
5. Badekila S., Nayak D. (2018). Pharmaceutical Analytical Standardization using Bhadhara yantra. *Journal of Ayurveda and Holistic Medicine*, 6(3), pp 1-17.
6. Mallick A., Bhattacharya S., Bhaghe D. S. (2013). Ayurvedic Drugs from Marine Originates. *International Journal of Pharmaceutical Research and Development*, 5 (1), pp 11-20.
7. Satpute A.D. (2013). Rasendra Sarasangraha. 1st ed. Varanasi: Chaukhambha Orientalia.
8. Badekila S., Nayak D. (2018). Pharmaceutical Analytical Standardization using Bhadhara yantra. *Journal of Ayurveda and Holistic Medicine*, 6 (3), pp 1-17.
9. Samuel P., Prince L., Prabakaran P. (2011). Ocean the inviolate Source of Pharmaceutical leads and drug metabolites. *Journal Title world J*, 1 (10), pp 74-91.
10. Mallick A., Bhattacharya S., Bhaghe D. S. (2013). Ayurvedic Drugs from Marine Originates. *International Journal of Pharmaceutical Research and Development*, 5 (1), pp 11-20.
11. Pandit S., Sur T.K., Jana U., Bhattacharya D., Debnath P.K. (2016). Anti- ulcer effect of Shankha Bhasma in Rats – A Preliminary Study, *Indian Journal of Pharmacology*, 32, pp 378-380.
12. Sinha S., Singhe R.K, Kumar N., Sinngh S.P., Rekha D. (2021). Preparation and Exploration of Physical Properties of Calcium bases Indian Origin Ayurvedic Medicine – *Shankha Bhashma* (Marine Druge) as Nanomaterials for its Applications. *Journal of Natural Remedies*, 21 (3), pp 225-234.
13. Seth A., Maurya S.K., Srivastava A. (2014). Formulation Development, Characterization and Estimation or Acid Neutralization Capacity of Shankh Bhasma Tablets for the Tretments of Dyspepsia. *International journal of pharmacy and pharmaceutical sciences*, 6 (2), pp 467-469.

14. Kamble S., Wanjari A., Rathi B., Rajput D. (2021). Pharmaceutico - Analytical study of Mukta shukti pishti and Mukta Shukti Bhasma and Comparative Evaluation of their relative oral Bioavailability. *Journal of Pharmaceutical Research*, 33(31A), pp 1-9.
15. Kumar R., Kumar A., Mitra A., Hazra J., Sharma L. (2015). Efficacy of Kaparda Bhasma, A popular Ayurvedic Drug in the management of Amlapitta. *European Journal of Pharmaceutical and Medical Research*, 2 (5) pp 394-401.
16. Kamble S., Wanjari A., Rathi B., Rajput D. (2021). Pharmaceutico - Analytical study of Mukta shukti pishti and Mukta Shukti Bhasma and Comparative Evaluation of their relative oral Bioavailability. *Journal of Pharmaceutical Research*, 33 (31A), pp 1-9.
17. Perera B.P.R. (2017). Hand book of Rasa Shastra.1 st ed. Colombo: S. Godage and Brothers (pvt) Ltd.
18. WHO. (1998). Quality control methods for medicinal plant materials. WHO Press. Switzerland. 9-42.
19. Volumetric analysis (5) A Back Titration. (2016). Available from: <http://derekcarrsavvy-chemist.blogspot.com/2016/01/volumetric-analysis-5-back-titration.html>
20. Eamlamnam K., Patumraj S., Visedopas N., Thong-Ngam D. (2006). Effects of Aloe vera and sucralfate on gastric microcirculatory changes, cytokine levels and gastric ulcer healing in rats. *World Journal of Gastroenterology*: 7;12(13) pp 2034-2039. doi: 10.3748/wjg.v12.i13.2034. 29) Perera, B.P.R. (2017). Hand book of Rasa Shastra.1 st ed. Colombo: S.Godage and Brothers (pvt) Ltd.

Identifying the type of impairments among children with disabilities: An observational study of the Divulapitiya Divisional Secretariat Area

Weerakoon W.A.S.S.^{*1}, Gunawardhana R.M.R.², Kaushalya H.B.D.³ and Fernando I.M.O.⁴

Abstract

Children with disabilities include those who have long-term physical, mental, intellectual, or sensory impairments which, in combination with various barriers, may hinder their full and effective participation in society on an equal basis, according to the Convention on the Rights of Persons with Disabilities. The demographics of children with impairments are quite different. They include children who were born with an inheritable condition that impacts their physical, mental, or social development; those who had an infection, serious injury, or nutritional shortfall that had long-term functional effects; and those who were exposed to environmental toxins that caused learning disabilities or developmental delays. Children with impairments might also be individuals whose difficult life situations cause them to experience anxiety or sadness. There are about 240 million children worldwide who struggle with disabilities. In Sri Lanka, 1.67% of children aged 5-14 were identified as disabled in 2012. An observational study was conducted in the Divulapitiya divisional Secretariat area to understand the type of impairments among children with disability. The study found that 46% of the 72 children had brain function disorders (*Manodaurbalya*), 33% had nervous system disorders, 1.4% had muscular dystrophies, 1.4% had visual disorders, 1.4% had mutism disorders, and 2.7% had growth deformities. The study highlights the need for more community knowledge, better

resource allocation, and focused interventions to identify and manage these children. The findings emphasize the need for research conducted in all divisional secretariats to increase awareness and support children with disabilities nationwide.

Keywords: Children, Disabilities, Observational study

Introduction

Children with disabilities are a varied population that requires specialized solutions due to their many sorts of disabilities. To understand the unique requirements and problems of these youngsters in various locations in Sri Lanka, local studies are essential. This study aims to identify the various types of impairments among children with disabilities in the Divulapitiya Divisional Secretariat area and examine their impact on the community, healthcare, and educational services. The research will explore physical, sensory, intellectual, developmental, psychological, and demographic factors, as well as the challenges these children face in accessing community support, healthcare, and education. The national disability data offer a broad picture, but localized research that can guide focused treatments and policy is extremely limited. Concerning these services, the study intends to determine the most prevalent forms of developmental, psychological, intellectual, physical, sensory, and demographic challenges that these children encounter.

¹Department of Shalya Shalakya and Prasutitantra Kaumarabhrithya Faculty of Indigenous Medicine, University of Colombo, Sri Lanka.

²Faculty of Medicine and Health Sciences, Keele University, Newcastle, United Kingdom.

³Unit of Research and Development of Natural Products, Faculty of Indigenous Medicine, University of Colombo, Sri Lanka.

⁴Community Medical Officer, Divapitiya, Sri Lanka.

**Correspondence: Weerakoon W.A.S.S., Faculty of Indigenous Medicine, University of Colombo, Sri Lanka. Email: dr.sarojaweerakoon@fim.cmb.ac.lk*

Children with disabilities require continuous attention and assistance beyond the expected amount for their age group. The Convention on the Rights of Persons with Disabilities (CRPD) defines children with disabilities as those who have difficulties with chronic physical, mental, intellectual, or sensory impairments that may impede their full and effective involvement in society¹. The World Health Organization defines disability in three distinct instances: impairment affecting a person's physical structure or abilities, or their mental state; loss of limbs, eyesight loss, or memory loss are a few instances of impairments. Activity constraints include trouble walking, hearing, seeing, or solving problems². To adequately address the needs of children with disabilities and eliminate current inequities, the Sustainable Development Goals (SDGs) place a significant focus on policy interventions³. These children frequently experience challenges within their families as well as their communities. Further, they share disproportionately and fall behind normal children in terms of education, health care, and social protection⁴.

As estimated by UNICEF, approximately 10% of children aged 0–19 years globally necessitate assistance to meet their specific health and social demands⁵. As evidenced by the Census of Population and Housing in Sri Lanka, 1.67% of children aged 5–14 were categorized as disabled in Sri Lanka⁶. This emphasizes the significance of addressing children with disabilities both locally and globally.

International Classification of Functioning of Disability and Health (ICF) of WHO and the Washington Group on Disability Statistics offer key frameworks for regulating disability evaluation⁷. Additionally, the CRPD emphasizes the obstacles that children with disabilities experience in society through implementing the definition of those children in the same year⁸. Additionally, the worldwide estimated number of children with disabilities has increased from 150 million in 2001 to 240 million in 2024⁹, necessitating immediate global and local discussions and interventions.

The Brazilian typology of care divides Children with disabilities into development, technology, health,

modified standards, and mixed demands. The development needs include children with a neuromuscular impairment who need social and psychomotor rehabilitation¹⁰. Technology dependence exists within the desire for technology. There are drug-dependent individuals in the medical sector. Children in modified standard demand depend on adjustments to their regular care routine. The mixed category includes one or more criteria together. This categorization emphasizes the varied nature and complexities of children with disabilities¹¹.

Children with disabilities show dependent behavior to fulfill their needs, and this behavior may lead to stress for families and more specifically parents of children with disabilities¹². In considering this, the growth of Children in modified standard demand depends on adjustments to their regular care routine. The mixed category includes one or more criteria together. This categorization emphasizes the varied nature and complexities of children with disabilities¹¹ could be associated with parental stress. The burden of providing this care can have an impact on both the quality of life of parents of children with disabilities and the children themselves¹³.

Sri Lanka has made great legislative strides in the area of disability rights with the enactment of the 1996 Act for the Protection of Rights of Persons with Disabilities and constitutional protections¹⁴. Due to societal challenges, such as persistent stigmas and negative attitudes about impairments, there are significant barriers to the effective execution of these rights. In addition, delivering services to a significant proportion of disabled people becomes a challenge when resources are limited, particularly in middle-income and low-income countries like Sri Lanka¹⁵.

Research done in Turkey, it has found that countries such as the United States, England, Australia, the Netherlands, Canada, Italy, Taiwan, Spain, and China, have become prominent contributors in the field of research on children with disabilities. Further, it illustrates that there is a relationship between the h-index of countries and the quantity of research they produce on children with

disabilities, which shows an interesting pattern. Furthermore, data indicates that there is a positive correlation between the (Gross Domestic Product) GDP per capita of a country and its h-index¹⁶. However, countries such as Sri Lanka are falling behind as it has been recorded fewer research projects related to children with disabilities. Despite having few resources in countries like Sri Lanka, it makes a substantial contribution to the field of children with disabilities. This emphasizes the need to promote and expand research that benefits children with disabilities.

The purpose of this observational study is to examine the distribution and prevalence of impairments among children with disabilities aged 5 to 19 years in the Divisional Secretariat of Divulapitiya, Sri Lanka. Additionally, find out more about the approaches taken to manage them and address the health problems associated with them in this specific area.

The Divulapitiya Divisional Secretariat area is comprised of 123 Grama Niladhari divisions, within which special centers serve children with disabilities. Three of these centers are attached to schools and the other one functions by volunteers. This study was focused on four distinct centers. Those centers were The Ananda Vidyalaya Center for children with disabilities in Maradaghamula, Kudagammana Maha Vidyalaya, the Center for children with disabilities, Ullalapola Kanishta Vidyalaya Center for children with disabilities and Halpe's Footpath Center.

These centers are essential to the education of children between the ages of 5 to 19. The Maradaghamula Center also functions as an institution for vocational training. In addition to offering educational programs, these play an important part in the community by supporting children with disabilities who are under five years old and have been referred to Ayurveda medical clinics at the secretariat division.

This study focuses on children with disabilities and focuses on their background for the first time in the Divulapitiya Divisional Secretariat area as well as in Sri Lanka. The growing number of children with

disabilities locally as well as globally highlights the necessity of thorough discussions and research to develop interventions and policies such as Advancement and Protection of Rights of Persons with Disabilities, that address the unique requirements of these children. These interventions should especially focus on the health and well-being of the children. It is also crucial to assess the effects on families of children with disabilities, and this illustrates the need for additional study in similar settings.

Methodology

Study design

This study was planned as an observational study to investigate the prevalence and distribution of children with disabilities under different age categories in the Divulapitiya Divisional Secretariat area, Sri Lanka.

Study population

The study population comprised 72 children between the ages of 5 and 19 years. All are identified as children with disabilities who live within the Divulapitiya Divisional Secretariat area.

Data collection

The data were obtained from clinical observation records compiled during a special clinic conducted by Ayurvedic Community Medical Officers. The observations focused on a range of impairments, such as muscular dystrophies, visual disorders, mutism disorders, growth deformities, Down syndrome, ASD (autism spectrum disorder), ADHD (attention deficit hyperactivity disorder), nervous system disorders, including cerebral palsy (global developmental delay and mental development delay) and Meningomyelocele.

Data analysis

The MS Excel 2010 software was used for statistical analysis. The collected data were systematically arranged in an MS Excel spreadsheet. Averages and percentages were calculated to provide a comprehensive understanding of the prevalence of different impairments among the children with

disabilities in the study population. After the statistical analysis, the data were interpreted to draw meaningful conclusions. The study aimed to identify patterns, trends, and associations among the various impairments observed in children with disabilities within the Divulapitiya Divisional Secretariat area.

Results and Discussion

Among the 72 children with disabilities included in this study, males made up the majority (59.72%). The research sample was then split up into age groups to investigate the characteristics and variables relevant to every developmental stage in Divulapitiya Divisional Secretariat area. Table 1 illustrates the gender distribution of the children with disabilities in the study sample. The study population showed a higher proportion of males compared to females, as reflected in the demographic distribution table.

Table 1: Gender-wise Classification of children with disabilities in the Study Population

| Gender | Male | Female |
|------------|--------|--------|
| Amount | 43 | 29 |
| Percentage | 59.72% | 40.27% |

Table 2 illustrates the distribution of children with disabilities across different age groups, categorized by gender. The age grouping used in this study follows the classification set by the World Health Organization in 2013¹⁷.

The age-wise distribution indicates that most children with disabilities in the study fall within the 5-9 age group. The greater percentage of males, especially in the youngest age range, possibly suggests a need for targeted interventions and support services that address the specific challenges faced by young males with disabilities in the Divulapitiya Divisional Secretariat area.

Table 2: Age-wise Distribution of children with disabilities by Gender

| Age groups | Gender | | | |
|-------------|--------|------------|---------|------------|
| | Males | Percentage | Females | Percentage |
| 5-9 years | 21 | 29.16% | 11 | 15.27% |
| 10-14 years | 09 | 12.5% | 09 | 12.5% |
| 15-19 years | 13 | 18.05% | 09 | 12.5 % |
| Total | 43 | 59.72% | 29 | 40.27% |

Table 3 presents the distribution of children with disabilities in Divulapitiya based on disease type. Out of 72 children who attended the medical clinic conducted by the Ayurveda community medical officers it could classify the children based on six different types of diseases. The count in each category represents the number of individuals identified with the respective conditions.

Table 3: Distribution of children with disabilities by Type of Disease

| Type of Disease | Name of Disease | Amount | Percentage |
|---|--------------------|------------------------------|------------|
| Brain function disorders (33) (<i>Mano daurbalya</i>) | Down syndrome | 13 | 18% |
| | ASD | 05 | 6.94 % |
| | ADHD | 15 | 20.83% |
| Diseases related to the Nervous System (24) | Cerebral palsy | Mental development delay -08 | 11.11% |
| | | Global development delay- 12 | 16.66% |
| | Meningo myelocoele | 04 | 5.55% |
| Learning Disability | | 10 | 13.8% |
| Muscular Dystrophies | DMD | 01 | 1.38% |
| Visual Defects | | 01 | 1.38% |
| Spinal cord-related disorders | Scoliosis | 01 | 1.38% |
| Mutism | | 01 | 1.38% |
| Growth deformities | Dwarfism | 02 | 2.70% |

It is evident from the above table that a considerable portion of the children with disabilities in Divulapitiya have brain function disorders, with Down syndrome, ASD, and ADHD. It can be further observed that out of the three diseases; the prevalence of ADHD is significant.

The conducted study has significantly contributed to understanding the relationship between ADHD and ASD through the observed case record forms. The findings provide a clear comorbidity between ADHD and ASD, as evidenced by the presence of ADHD features among individuals with ASD in the study population. This observation aligns with existing literature, which reports a prevalence of ADHD in people with ASD ranging from 50% to 70%. (18). The study indicated a high frequency of nervous system-related problems, which constitutes the third highest category of diseases. This category includes mostly health conditions like meningomyelocele and cerebral palsy. The study highlights an important comparison between mental development delay and global development delay within the subgroup of cerebral palsy. The results indicate that there is a greater incidence of global developmental delay than mental developmental delay, which aligns with the perspective expressed by the American Academy of Neurology¹⁹. Further, these results highlight the multifaceted nature of health problems among children with disabilities in Divulapitiya.

Table 4 shows the prevalence of children with disabilities associated with nutrient deficiency in Divulapitiya across various age groups. Nutritional deficiencies, which are a major health concern, were examined under three age brackets, providing insights into the distribution of malnutrition in the study population.

The obtained results show that malnutrition was most prevalent among disabled children aged 5–9, and least common in those aged 15–19.

Table 4: Prevalence of children with disabilities associated with nutrient deficiency as per age groups

| Name of Disease | Age group (Years) | Amount | Prevalence |
|------------------------|-------------------|--------|------------|
| Nutritional deficiency | 5-9 | 12 | 46.15% |
| | 10-14 | 08 | 30.76% |
| | 15-19 | 06 | 23.07% |
| Total | | 26 | 100% |

Table 5 presents the distribution of parental occupation among children with disabilities in the desired study location. This data can be used to understand how parental occupation may affect the well-being of children. The graph shows that parents come from a diverse range of occupational backgrounds, including self-employment, government service, private sector work, and unemployment. The relevant columns provide the number of parents, and the prevalence is shown in brackets.

The predominant occupation among fathers of children with disabilities in Divulapitiya is self-employment. The majority of these self-employed fathers are mainly engaged in farming and business and minority being unemployed. There is a marginal change in the prevalence of fathers in government and private sectors. Conversely, among mothers, a considerable majority are unemployed, while a minority are engaged in government work. The variations in parental occupations across different disease conditions suggest potential impacts on the well-being of children with disabilities.

However, further studies are needed to study the potential relationship between parental employment and the type of disability. Additionally, should focus on determining whether parents of children with disabilities had to give up their jobs to care for them, as well as the way family economies affect the general well-being and the quality of life of both the parents and the children with disabilities.

Table 6 elaborates on the educational background of parents of children with disabilities in Divulapitiya, categorized by disease type. In this tabulation, the educational levels of both fathers and mothers are

outlined, ranging from those who have not attained formal education to those with higher education qualifications. In each column, it mentioned the amount as well as prevalence are mentioned based on the total number of cases.

The table shows that the majority of parents were educated and had finished their schooling up to ALs. It also shows that parents came from a variety of educational backgrounds. It is also further observed that, regardless of parental education, dietary deficits are common throughout a range of educational levels. Overall results encourage more research to be carried out to find out if there is any connection between the type of disease, parental education, and its effect on the well-being of children with

disabilities. This study provides the framework for further research and specially designed interventions based on the particular requirements connected to each type of disease.

The data in Table 7 describe the prevalence of family history among children with disabilities with different health conditions in Divulapitiya. It indicates the number of cases where family history is present or absent for each specific condition.

The majority of cases across various diseases exhibit the absence of a family history, indicating that these conditions are not primarily hereditary. ADHD and ASD reflect that there is a relationship more toward family history.

Table 5: Distribution of parental occupation by disease type in children with disabilities

| Disease Type | Parental Occupation | | | | | | | |
|--|----------------------|-------------------|-------------------|------------------|-----------------|-------------------|-------------------|----------------------|
| | Father | | | | Mother | | | |
| | Govern- - ment | Private sector | Self- employed | No occupation | Govern- ment | Private sector | Self- employed | No occupat ion |
| Down Syndrome | 03 (4.16%) | 04 (5.55%) | 05 (6.94%) | 01 (1.38%) | 03 (4.16%) | 04 (5.55%) | 02 (2.77%) | 04 (5.55%) |
| ASD | 02 (4.16%) | 02 (4.16%) | 01 (1.38%) | - | 01 (1.38%) | 03 (4.16%) | 01 (1.38%) | - |
| ADHD* | 04 (5.55%) | 04 (5.55%) | 06 (4.16%) | -* | 04 (5.55%) | 03 (4.16%) | 02 (4.16%) | 06 (8.33%) |
| Cerebral palsy (Mental Development Delay) | 01 (1.38%) | 02 (4.16%) | 04 (5.55%) | 01 (1.38%) | - | 01 (1.38%) | 02 (4.16%) | 05 (6.94%) |
| Cerebral palsy (Global Development Delay) | 05 (6.94%) | 02 (4.16%) | 04 (5.55%) | 01 (1.38%) | 01 (1.38%) | 02 (4.16%) | 03 (4.16%) | 06 (4.16%) |
| Meningomyelo cele | 01 (1.38%) | 01 (1.38%) | 02 (4.16%) | - | - | 01 (1.38%) | 01 (1.38%) | 02 (4.16%) |
| DMD | 01 (1.38%) | - | - | - | - | - | - | 01 (1.38%) |
| Scoliosis | 01 (1.38%) | - | - | - | - | - | - | 01 (1.38%) |
| Dwarfism | - | 01 (1.38%) | 01 (1.38%) | - | 01 (1.38%) | - | - | 01 (1.38%) |
| Visual disorders | - | 01 (1.38%) | - | - | - | - | 01 (1.38%) | - |
| Mutism disorders* | - | - | - | -* | - | - | 01 (1.38%) | - |

* Indicates cases where the father has passed away

Table 6: Distribution of parental education of children with disabilities by disease type

| Disease Type | Parental education | | | | | | | | | |
|---|----------------------|---------------|---------------|----------------|------------------|----------------------|---------------|---------------|----------------|------------------|
| | Father | | | | | Mother | | | | |
| | Not attain to school | Up to grade 5 | Up to O/L | Up to A/L | Higher education | Not attain to school | Up to grade 5 | Up to O/L | Up to A/L | Higher education |
| Down Syndrome | - | - | 05 (6.94%) | 07 (9.72%) | 01 (1.38%) | - | - | 07 (9.72%) | 05 (6.94%) | 01 (1.38%) |
| ASD | - | - | 01 (1.38%) | 03 (4.16%) | 01 (1.38%) | - | - | 02 (2.77%) | 03 (4.16%) | - |
| ADHD* | - | - | 03 (4.16%) | 11 (15.27%) | 01 (1.38%) | - | - | 03 (4.16%) | 10 (13.33%) | 02 (2.77%) |
| Cerebral palsy (Mental Development Delay) | - | 01 (1.38%) | 03 (4.16%) | 01 (1.38%) | - | - | - | 05 (6.94%) | 03 (4.16%) | - |
| Cerebral palsy (Global Development Delay) | - | 01 (1.38%) | 04 (5.55%) | 06 (8.33%) | 01 (1.38%) | - | - | 06 (8.33%) | 06 (8.33%) | - |
| Meningo myelocele | - | - | 02 (2.77%) | 02 (2.77%) | - | - | - | 01 (1.38%) | 03 (4.16%) | - |
| DMD | - | - | - | 01 (1.38%) | - | - | - | - | 01 (1.38%) | - |
| Scoliosis | - | - | - | 01 (1.38%) | - | - | - | - | 01 (1.38%) | - |
| Dwarfism | - | - | - | 02 (2.77%) | - | - | - | - | 02 (2.77%) | - |
| Visual disorders | - | - | - | 01 (1.38%) | - | - | - | - | 01 (1.38%) | - |
| Mutism disorders* | - | - | - | 01 (1.38%) | - | - | - | 01 (1.38%) | - | - |

* Indicates cases where the father has passed away.

Table 7: Family history of children with disabilities by disease type

| Name of Disease | Family History present | Family History absent |
|---|------------------------|-----------------------|
| Down syndrome | 06 (44.15%) | 07 (53.84%) |
| ASD | 03 (60%) | 02 (40%) |
| ADHD | 08 (53.33%) | 07 (46.66%) |
| Cerebral palsy (Mental Development Delay) | 03 (37.5%) | 05 (62.5%) |
| Cerebral palsy (Global Development Delay) | 4 (33.33%) | 08 (66.66%) |
| Meningomyelocele | - | 04 (100%) |
| DMD | - | 01(100%) |
| Scoliosis | - | 01 (100%) |
| Dwarfism | - | 02 (100%) |
| Visual disorders | 01 (100%) | - |
| Mutism disorders | 01 (100%) | - |

The majority of cases do not have a family history, highlighting the impact of environmental and nutritional factors in this category. Further genetic studies and detailed family histories can contribute to a deeper understanding of the aetiology of these conditions, guiding more effective interventions and support strategies.

Table 8 provides an overview of the age at which children with disabilities in Divulapitiya were first diagnosed and categorized by different health conditions. All cases of Down syndrome were diagnosed at birth, emphasizing the congenital nature of Down Syndrome.

Table 8: Age at first diagnosis for children with disabilities by disease type

| Name of Disease | At birth | At the age of 1 year | At the age of 2 years | Less than 5 years | More than 5 years |
|---|-----------|----------------------|-----------------------|-------------------|-------------------|
| Down syndrome | 13 (100%) | - | - | - | - |
| ASD | - | - | 02 (40%) | 03 (60%) | - |
| ADHD | - | - | 01 (6.67%) | 10 (66.7%) | 04 (26.7%) |
| Cerebral palsy (Mental Development Delay) | - | 08 (100%) | - | - | - |
| Cerebral palsy (Global Development Delay) | - | 12 (100%) | - | - | - |
| Meningomyelocele | 04 (100%) | | | | |
| DMD | - | - | - | 01 (100%) | - |
| Scoliosis | - | - | - | 01 (100%) | 01 (100%) |
| Dwarfism | - | 01 (50%) | 01 (50%) | - | - |
| Visual disorders | - | - | - | 01 (100%) | - |
| Mutism disorders | - | - | 01 (100%) | - | - |

Table 9: Parental awareness of children with disabilities by disease type

| Name of Disease | Awareness present | Awareness absent |
|---|-------------------|------------------|
| Down syndrome | 07 (53.8%) | 06 (46.1%) |
| ASD | 03 (60%) | 02 (40%) |
| ADHD | 09 (60%) | 06 (40%) |
| Cerebral palsy (Mental Development Delay) | 06 (75%) | 02 (25%) |
| Cerebral palsy (Global Development Delay) | 11 (91.7%) | 01(8.3%) |
| Meningomyelocele | 04 (100%) | - |
| DMD | 01 (50%) | 01(50%) |
| Scoliosis | 01 (100%) | - |
| Dwarfism | 02 (100%) | - |
| Visual disorders | 01 (100%) | - |
| Mutism disorders | 01 (100%) | - |

Table 10: Focus on continuous treatments for children with disabilities by disease type

| Name of Disease | Focus on continuous treatments | Not focused on continuous treatments |
|---|--------------------------------|--------------------------------------|
| Down syndrome | - | 13 (100%) |
| ASD | 01 (20%) | 04 (80%) |
| ADHD | 02 (11.8%) | 15 (88.2%) |
| Cerebral palsy (Mental Development Delay) | 05 (62.5%) | 03 (37.5%) |
| Cerebral palsy (Global Development Delay) | 09 (75%) | 03 (25%) |
| Meningomyelocele | 04 (100%) | - |
| DMD | 01 (100%) | - |
| Scoliosis | - | 01(100%) |
| Dwarfism | - | 02 (100%) |
| Visual disorders | 01(100%) | - |
| Mutism disorders | - | 01(100%) |

Table 11: Further management of children with treatments by disease type

| Name of disease | Can be managed by Community Medical Officers | Directed to the National Ayurveda Teaching Hospital for further treatments |
|---|--|--|
| Down syndrome | 06 (40%) | 07 (60%) |
| ASD | - | 05 (100%) |
| ADHD | - | 15 (100%) |
| Cerebral palsy (Mental Development Delay) | - | 08 (100%) |
| Cerebral palsy (Global Development Delay) | - | 12 (100%) |
| Meningomyelocele | - | 04 (100%) |
| DMD | - | 01 (100%) |
| Scoliosis | - | 01 (100%) |
| Dwarfism | 02 (100%) | - |
| Visual disorders | - | 01 (100%) |
| Mutism disorders | 01 (100%) | - |

The majority of ASD cases were diagnosed between the ages of 2 and 5 years, indicating that symptoms may become more noticeable as children reach certain developmental milestones. ADHD diagnoses occurred across various age groups, with the majority being identified before the age of 5, highlighting the early onset of symptoms. Cerebral Palsy with (Mental /Global Development Delays), both types were diagnosed by the age of 1 year, underlining the early recognition of developmental delays. Meningomyelocele, DMD, Dwarfism, Visual Disorders, and Mutism Disorders were predominantly diagnosed at birth or within the first year of life, indicating early detection.

Table 9 illustrates the level of awareness among parents regarding the condition of their children with disabilities. This information has been taken from a section of the case record form, assessing whether parents possess an understanding of their child's condition and are aware of the appropriate ways to interact and behave with them.

Parents of children with various disabilities, including Down syndrome, ASD, ADHD, and developmental delays, showed a reasonable level of awareness and understanding, and higher awareness was reported for conditions like meningomyelocele, scoliosis, dwarfism, visual disorders, and mutism.

Table 10 presents information about the extent to which parents or caregivers focus on providing continuous treatment for children with disabilities since the identification of the child's condition

Children with Meningomyelocele, DMD, and Visual Disorders receive consistent treatment, reflecting a strong commitment to their well-being. However, children with Down Syndrome, Scoliosis, Dwarfism, and mutism often lack continuous treatment. For children with ASD, ADHD, and various forms of Cerebral Palsy, maintaining consistent treatment presents challenges, indicating areas where support and intervention are needed to ensure continuous care.

Table 11 provides information on the recommended approach for managing children with disabilities following treatment. It depicts the percentage of cases for each disease type that can be managed by Ayurvedic Community Medical Officers and those directed to the National Ayurveda Teaching Hospital for further treatment.

Down Syndrome, Autism, ADHD, Cerebral Palsy (Mental Development Delay / Global Development Delay), Meningomyelocele, DMD, Scoliosis, Visual Disorders, and Mutism Disorders cases, show a significant percentage have been directed to the National Ayurveda Teaching Hospital for further treatment. For Dwarfism, a notable percentage can be managed by Ayurvedic Community Medical Officers, suggesting that ongoing care and treatments can be provided at the community level.

Conclusion

This observational study in the Divulapitiya Divisional Secretariat area of Sri Lanka provides valuable insights into the distribution and prevalence of impairments among children with disabilities aged 5 to 19. The study highlights varying parental awareness and challenges related to continuous treatment for different conditions. Notably, conditions like ADHD and nervous system disorders were more prevalent. The findings emphasize the need for targeted interventions and further research with a larger, more diverse sample to better understand the challenges and improve support services for children with disabilities in Sri Lanka.

References

1. UNICEF. Inclusive Education. (2017) Understanding Article 24 of the Convention on the Rights of Persons with Disabilities. Geneva 10 Switzerland: UNICEF Regional Office for Europe and Central Asia; 2017.
2. CDC. Disability and Health. (2024), Disability and Health Overview. Available from: <https://www.cdc.gov/disability-and-health/about/index.html> [cited 2024 May 11].

3. Hayes A.M., Bulat J., (2017), Disabilities Inclusive Education Systems and Policies Guide for Low- and Middle-Income Countries [Internet]. Research Triangle Park (NC): RTI Press; 2017 (RTI Press Occasional Papers). Available from: <http://www.ncbi.nlm.nih.gov/books/NBK554622/> [cited 2024 Jan 19].
4. Houtrow A., Jones J., Ghandour R., Strickland B., Newacheck P., (2012), Participation of Children with Special Health Care Needs in School and the Community. *Acad Pediatr.* 2012;12(4):326–34.
5. Kruk M.E., Lewis T.P., Arsenault C., Bhutta Z.A., Irimu G., Jeong J., *et al.* (2022), Improving health and social systems for all children in LMICs: structural innovations to deliver high-quality services. *Lancet.* 2022 May 7;399(10337):1830–44.
6. Census of Population and Housing [Internet]. Department of Census and Statistics; 2012. Available from: <http://www.statistics.gov.lk/#gsc.tab=0>
7. Madans J.H., Loeb M.E., Altman B.M., (2011), Measuring disability and monitoring the UN Convention on the Rights of Persons with Disabilities: the work of the Washington Group on Disability Statistics. *BMC Public Health.* 2011 May 31;11(4): S4.
8. Kiru E., Cooc N., (2018), A Comparative Analysis of Access to Education for Students with Disabilities in Brazil, Canada, and South Africa. *Journal of International Special Need Education.* 2018;21(2).
9. Olusanya B.O., Kancherla V., Shaheen A., Ogbo F.A., Davis A.C., (2022), Global and regional prevalence of disabilities among children and adolescents: Analysis of findings from global health databases. *Front Public Health.* 2022 Sep 23; 10:977453.
10. Simonasse M.F., Medeiros de Moraes J.R.M. (2015), Integrative review of the literature. *Journal of research fundamental care* online. 2015 Jul;5(3).
11. Barreiros C.F.C., Gomes M.A. de S.M., Mendes Júnior S.C. do S. (2020), Children with special needs in health: challenges of the single health system in the 21st century. *Rev Bras Enferm.* 2020 Nov 11;73: e20190037.
12. Cheng A.W.Y., Lai C.Y.Y. (2023), Parental stress in families of children with special educational needs: a systematic review. *Front Psychiatry.* 2023 Aug 10; 14:1198302.
13. Sulaimani G.H., Kamel S., Alotaibi G., Telmesani N. (2023), Quality of Life Among Family Caregivers of Disabled Children in Saudi Arabia. *Cureus.* 2023, Jul;15(7): e41320.
14. Campbell F.K. (2013), A Review of Disability Law and Legal Mobilisation in Sri Lanka. *LST Review.* 2013 Jun;23(308).
15. Karunarathne R. (2021), A Brief Review of Disability Rights and Welfare in Sri Lanka. *Sri Lanka Journal of Social Development.* 2021 Nov;01(07).
16. Arslan R., Orbay K., Orbay M., (2024), A bibliometric analysis of publications on special education between 2011 and 2020. *Hungarian Educational Research Journal* [Internet]. 2023 Sep 28;1(aop). Available from: <https://akjournals.com/view/journals/063/aop/article-10.1556-063.2023.00212/article-10.1556-063.2023.00212.xml> [cited 2024 Jan 19]
17. World Health Organization. Age Group Codelist [Internet]. 2013 Available from: <https://apps.who.int/gho/data/node.searo-metadata.AGEGROUP> [cited 2024 Jan 19].
18. Hours C., Recasens C., Baleyte J.M., (2022), ASD and ADHD Comorbidity: What Are We Talking About? *Front Psychiatry.* 2022 Feb 28; 13:837424.
19. Sharma A.R., Siddiqui M.S., Magar S., Kale A., Nelanuthala M., Singh S.P. (2023), The Etiological Profile of Global Developmental Delay at a Tertiary Care Hospital in India: An Observational Study. *Cureus.* 2023 Jun;15(6): e41066

Management of *Thusta viranam* (Chronic diabetes mellitus associated venous leg ulcer) by using Traditional treatment regimen: A case study

Shomesh V.¹, Yameni K.², Keerthika C.², Kasthuri S.², Soruban T.³ and Subaveena S.²

Abstract

Chronic wounds, such as venous leg ulcers, are common and often persist for weeks or months. One type, *Thusta viranam*, described in Traditional and Siddha literature, is characterized by deep, purulent, foul-smelling wounds with severe pain, swelling, and itching. Traditional and Siddha medicine recommends various topical and oral treatments to promote healing. *Punsudar thailam*, mentioned in *Anuboga Vaithiya Navaneedha Thirattu*, is used for wound healing and contains purified Sulphur (*Ganthagam*) and castor oil. This case study investigates the efficacy of *Punsudar thailam* in treating a *Thusta viranam* (Chronic diabetes mellitus associated venous leg ulcer). A 52-year-old female with a three months history of a painful, swollen, foul-smelling wound due to varicose veins, located above the lateral malleolus of her left leg, was admitted to the Siddha Teaching Hospital in Kaithady. The patient also had a history of diabetes, hypertension, dyslipidaemia, and fatty liver disease. She was diagnosed as *Thusta viranam* (chronic diabetes mellitus associated venous leg ulcer) and treated with wound cleaning using *Panjathuvarpi* decoction (*Kudineer*), followed by *Punsudar thailam* application and oral internal medicines such as *Neermulli* decoction (*Kudineer*), *Pattolathy peerku* decoction (*Kudineer*), *Sudarsana chooranam*, *Chandraprabha vati*, and *Vallarai chooranam*. The treatment was evaluated weekly through wound measurements and photographs using the Photographic Wound Assessment Tool (PWAT). Over a period of 29 days, weekly evaluations showed

a reduction in wound size from 5cm x 5cm to 3cm x 3.5cm with near complete closure (<0.1 cm). The PWAT score decreased from 17 to 07, indicating partial wound closure. These results suggest that *Punsudar thailam*, combined with internal medicines, effectively aids in healing *Thusta viranam* (chronic diabetes mellitus associated venous leg ulcer).

Keywords: Diabetes mellitus, *Panjathuvarpi kudineer*, *Punsudar thailam*, Traditional medicine, *Thusta viranam*

Introduction

Venous leg ulcers are, the most prevalent type of chronic lower leg ulcer worldwide¹. In Sri Lanka Chronic ulcers commonly arise from diabetes, nerve damage (neuropathy) associated with conditions such as leprosy, prolonged pressure on the skin (pressure ulcers), burns, poor venous circulation (venous ulcers), and inadequate arterial blood supply (arterial ulcers)². A chronic wound is defined as one that fails to heal in a timely manner, often persisting for weeks or months. Such wounds typically do not progress through the normal Stages of healing and can be caused by various factors³. According to the research finding the latest data on the subject have shown that the global prevalence of chronic wounds lies at 1.67 per 1000 population⁴. Most chronic wounds refer to chronic leg ulcers, and their computed worldwide prevalence is 1.51 per 1000 of these, the most reported ethology is venous disease⁵. Numerous types of wounds (*Viranam*) are described in Siddha and

¹Siddha Ayurveda Base Hospital, Pudhukudiyiruppu, Sri Lanka.

²Siddha Teaching Hospital, Kaithady, Sri Lanka.

³Post Graduate Institute of Indigenous Medicine, University of Colombo, Sri Lanka.

*Correspondence: Soruban. T., Post Graduate Institute of Indigenous Medicine, University of Colombo, Sri Lanka.
Email: sorruthiru@gmail.com

traditional literature. The Tamil English Dictionary by T.V. *Sambasivampillai* lists 22 types⁶. *Siddhar Aruvai Maruthuvam* describes 16 types,⁷ while *Sarabenthira Vaithiya Muraigal* text describes 2 types⁸. *Thusta viranam* is one of the types of wounds, characterized by deep, purulent smell wound with severe pain, swelling and itching⁸. *Punsudar thailam* is a prepared medicine for *Pilavai* (Carbuncle), *Pounthiram* (Fistula), *Pun* (Wound), *Katti* (Abscess), and *Vitpuruthy* (Tumour), as mentioned in *Anuboga vaithiya navaneedha thirattu*. Its ingredients are purified Sulphur (*Ganthagam*) and castor oil⁹. we attempted to use the same medicine for chronic wound to assess its wound healing potential.

Case Details

A 52 years old female patient was admitted to the IPD at Siddha Teaching Hospital, Kaithady, working as a Teacher from Tholpuram, Jaffna District. The patient had complaints with gradual onset, an oval-shaped wound due to varicose vein above the lateral malleolus of her left leg for three months associated with painful, swollen, foul-smelling, itchy, and weeping wound. She has a medical history of diabetes mellitus, hypertension, dyslipidaemia and fatty liver for 15 years. In 2002, She suffered by cellulitis in left lower leg and acute pyelonephritis.

Physical examinations revealed a single, oval shaped wound with irregular and rough margins. The wound base was covered with erythematous tissues in the central part few amounts of slough covers in margin areas and a small amount of foul-smelling discharge observed. The wound, measurement was 5cm x 5cm x 1cm, located above the lateral malleolus of the left leg, with surrounding hyperpigmentation, swelling, heat, and tenderness.

Procedure of Treatment

Internal procedure

The patient was treated according to the Traditional medicine line of treatment. On the first day, *Virechana poopathy* with a dosage of three tablets along with 10ml hot water was administrated on an empty stomach for purgation. On the second day, the patient underwent an oil bath using 30ml of gingelly

oil applied mainly to the head, chest, lower abdomen, and limbs, after 20 minutes got warm water bath. From the third day onwards, internal medicines were administrated. For first five days' management given for blood purification (Table 1). Second set of medicine (Table 2) given for twenty-four days for wound healing purpose. Diet was restricted with hospital food for diabetic management.

Table 1: Treatment procedure (Internal) for first five days

| Name of the drug | Dose and duration | Anupanam | |
|----------------------------|--|------------|--------|
| <i>Neermulli kudineer</i> | 60ml twice in a day before food for 5 days | | |
| <i>Sudarsana chooranam</i> | 2g twice in a day after food for 5 days | With water | normal |
| <i>Chadraprabha vatti</i> | 2 pills twice in a day after food for 5 days | With water | normal |

Table 2: Treatment procedure (Internal) for next twenty-four days

| Name of drug | Dose and duration | Anupanam | |
|------------------------------------|---|-------------------|--|
| <i>Paddolathi peercku kudineer</i> | 60ml twice a day before food for 24 days | | |
| <i>Sudarsana chooranam</i> | 02g twice a day after food for 24 days | With normal water | |
| <i>Chandraprabha vati</i> | 02 pills twice a day after food for 24 days | With normal water | |
| <i>Vallarai chooranam</i> | 01g early morning empty Stomach for 24 days | With normal water | |

External procedure

The patient's left lower leg was immersed in *Panjathuvarpi kudineer*, followed by wound cleansing using the same decoction. *Punsudar thailam* was applied topically, and the wound dressing was done daily. Weekly wound measurements and photographic assessments were

carried out to monitor healing progress. The outcome was assessed by reduction of size by using the PWAT Scale (Photographic Wound Assessment Tool). Wound measurement method for length and width measurement, placed the ruler over the wound, aligning it with the longest side. For depth measurement Placed a sterile cotton swap into the deepest part of the wound bed. Grasped the applicator where it meets the wound margin and places it against the ruler. wound that open but appear to have no depth, record depth as “<0.1 cm.

Results

Table 3 illustrates the weekly wound size measurements and Table 4 shows the PWAT score of before and after management of wound.

Table 3: Weekly wound size measurements

| Date | Length | Width | Depth |
|-----------------------------------|--------|-------|--------|
| 26.08.2024 (1 st day) | 5cm | 5cm | 1cm |
| 02.09.2024 (8 th day) | 4.5cm | 4.5cm | 0.2cm |
| 09.09.2024 (15 th day) | 4cm | 4.5cm | 0.1cm |
| 16.09.2024 (22 th day) | 3.5cm | 4cm | <0.1cm |
| 23.09.2024 (29 th day) | 3cm | 3.5cm | <0.1cm |

Table 4: PWAT score of before and after management of wound

| Item | Before | After |
|--|--------|-------|
| Size | 4 | 3 |
| Depth | 1 | 0 |
| Necrotic tissue type | 1 | 0 |
| Total amount of necrotic tissue | 1 | 0 |
| Granulation tissue type | 2 | 1 |
| Total amount of granulation tissue | 3 | 1 |
| Edges (directly touching and within 0.5cm of wound edge) | 2 | 0 |
| Peri ulcer skin viability | 3 | 2 |
| Total | 17 | 7 |

Figure 1 to Figure 4 shows the weekly progression of the wound.



Fig.1: Wound at 26.08.2024



Fig.2: Wound at 02.09.2024



Fig.3: Wound at 09.09.2024



Fig.4: Wound at 23.09.2024

Figures of 5 and 6 shows the wound images on follow up period



Fig.5: Wound at 30.12.2024



Fig.6: Wound at 24.03.2025

Discussion

The ingredients of polyherbal formulation *Neermulli kudineer* possessed predominantly diuretic, antimicrobial, anti-inflammatory, antioxidant activities, moderately immunomodulatory and minimally antidiabetic. Ingredients of *Neermulli kudineer* are *Hygrophila auriculata* (*Neermulli*), *Aerva lanata* (*Thengaipoo keerai*), *Cuminum cyminum* (*Sinna seeraham*), *Asparagus racemoses*

(Saathavaari), *Terminalia chebula* (Kadukkaai), *Emblica officinalis* (Nellikkaai), *Terminalia bellirica* (Thaantrikaai), *Santalum album* (Vensanthanam) and *Cymbopogon jwarancusa* (Vilaamichai)¹⁰.

The raw materials of *Paddolathi peercku kudineer* are *Terminalia chebula* (Kadukkai), *Terminalia bellirica* (Thaandrikai), *Emblica officinalis* (Nelli), *Asparagus racemosus* (Saaththavari), *Trichosanthes cucumerina* (Peipudol), *Tinospora cordifolia* (Seenthil), *Picrorhiza kurroo* (Kaduhurohini). *Trichosanthes cucumerina* is one of the main ingredients in *Paddolathi peercku kudineer* and it has anti-bacterial, anti-inflammatory, antioxidant activities and immunomodulatory activity¹¹.

Vallarai chooranam is a single herbal *chooranam*, its ingredient is *Vallarai* (*Centella asiatica*). The main chemical components of *C. asiatica* are important for wound healing. One of key compound, asiaticoside, helps produce type 1 collagen, which is important for skin health and prevents skin ageing. It also helps with the wound healing process by speeding up the movement of skin cells, encouraging cell growth, improving skin cell attachment and increasing the number of healthy skin cells¹².

Chandraprabha vati is an effective Ayurvedic remedy for managing diabetic complications. It contains a blend of medicinal herbs known for their potent anti-diabetic properties. This formulation helps regulate blood sugar levels and promotes vascular health, preventing the progression of foot ulcers^{13,14,16}. Additionally, *Chandraprabha vati* has anti-inflammatory effects¹⁵, offering relief from pain and swelling around open wounds. Its ingredients are *Cinnamomum camphora* (Katpoora), *Acorus calamus* (Vasampu), *Cyperus rotundus* (Korai), *Swertia chirata* (Nilavembu), *Tinospora cordifolia* (Seenthil), *Cedrus deodara* (Devatharu), *Curcuma longa* (Manjal), *Aconitum heterophyllum* (Athividayam), *Berberis aristata* (Maramanjai), *Piper longum* (Thippili), *Plumbago zeylanica* (Siththiramoolam), *Coriandrum sativum* (Koththamalli), *Terminalia chebula* (Kadukkai), *Terminalia bellirica* (Thandri), *Emblica officinalis* (Nelli), *Piper chaba* (Aanithippili), *Embelia ribes* (Vaividangam), *Zingiber officinale* (Inji), *Piper nigrum* (Milaku),

Piper longum (Thippali), *Operculina terpepethum* (Sivathai), *Baliospermum montanum* (Neeradi muththtu), *Cinnamomum tamala* (Thalisapathiri), *Cinnamomum zeylanicum* (Karuva), *Elettaria cardamomum* (Ealam), *Bambusa arundinaceae* (Moongil), *Commiphora mukul* (Gugul), Copper pyrite, Potassium carbonate, Sodium bicarbonate, Rock salt, Black salt, Ammonium chloride, Ferrum, Sugar and Aspet mineral pitch¹⁶.

Sutharsana chooranam possesses several pharmacological activities, including antipyretic¹⁷, antimicrobial^{18,19,20}, antimalarial^{20,21}, antiviral^{21,22}, and antidiabetic²³ effects. The raw materials used in the preparation of *Sutharsana chooranam* include, *Swertia chirata* (Nilavembu), *Trichosanthes dioica* (Kombupudal), *Ureria picta* (Sittirapaladai), *Jateorrhiza palmate* (Maramanjai), *Curcuma longa* (Manjal), *Cedrus deodar* (Devatharu), *Acorus calamus* (Vasambu), *Desmodium triflorum* (Sirupulladi), *Terminalia chebula* (Kadukkai), *Alhagi pseudalhagi* (Kanjori), *Rhus succedonia* (Karkadakasingi), *Solanum xanthocarpum* (Kandankaththari), *Zingiber officinale* (Inji), *Legenaria siceraria* (Suraikkai), *Naregamala alata* (Nilanarakam), *Azadiracta indica* (Vembu), *Piper longum* (Thippili), *Pavonia odorata* (Peramatti), *Hedychium spicatum* (Poolankilangu), *Inula racemose* (Puskaramoolam), *Terminalia bellirica* (Thandrikai), *Marsdenia tenacissima* (Perunkurinjan), *Emblica officinale* (Nelli), *Tinospora cordifolia* (Seenthil), *Picrorhiza kurroo* (Kadukurogini), *Plumbago zeylanica* (Venkodiveli), *Moringa oleifera* (Murungai), *Asparagus racemosus* (Saaththavari), *Berberis aristata* (Maramanjai), *Didymocarpus pedicellata* (Kalpaasi), *Nelumbo speciosum* (Thamarai), *Pinus roxburghii* (Seemaithevatharu), *Andropogon muricatus* (Vettiver), *Cinnamomum cassia* (Karuva), *Cinnamomum inners* (Elavangam), *Desmodium gangaticum* (Sirupulladi), *Ptychotis coptica* (Asamothakam), *Aconitum heterophyllum* (Athividayam), *Aegle marmelos* (Vilvai), *Piper nigrum* (Milaku), *Holarrhena antidysenterica* (Kudasappala) and *Glycyrrhiza glabra* (Athimathuram)¹⁷.

The raw materials of *Panchathuvarpi kudineer* are *Ficus bengalensis* (Aal), *Ficus recemosa* (Aththi), *Syzygium jambolanum* (Naaval), *Ficus religiosa* (Arasu) and *Thespesia populnea* (Poovarasu). It possesses pharmacological antimicrobial activity¹⁵.

This review explains the potential of these formulations, providing strong evidence for their effectiveness in wound management.

52-year-old female with diabetes mellitus and bilateral varicose vein presented with a 3-month-old chronic wound above the left lateral malleolus. Initial assessment showed a 5 cm x 5 cm x 1 cm wound. After 29 days of treatment, the wound size reduced to 3 cm x 3.5 cm x <0.1 cm, and the PWAT score decreased from 17 to 7, indicating partial wound closure. This improvement was attributed to appropriate wound dressing and internal medicine management.

Conclusion

The results suggested that *Punsudar thailam* with internal medicine is effective in the management of *Thusta viranam* (Chronic diabetes mellitus associated venous leg ulcer) and further clinical studies will be conducted in future.

References

1. Lakmal K., Hettiarachchi D., Cassim M.R. N., & Malalasekera A.P. (2022). A systematic review on clinical outcomes of human amniotic membrane preparations in the management of venous leg ulcers. *Sri Lanka Journal of Surgery*, 40(2).
2. Kumarasinghe S. P. W., Karunaweera N.D., & Ihalamulla R.L. (2000). A study of cutaneous myiasis in Sri Lanka. *International Journal of Dermatology*, 39(9), 689-694.
3. Bowers S., & Franco E. (2020). Chronic wounds: evaluation and management. *American family physician*, 101(3), 159-166.
4. Järbrink K., Ni, G., Sönnerngren H., Schmidtchen A., Pang C., Bajpai R., & Car J. (2016). Prevalence and incidence of chronic wounds and related complications: a protocol for a systematic review. *Systematic reviews*, 5, 1-6.
5. Nelson E. A., & Adderley U. (2016). Venous leg ulcers. *BMJ clinical evidence*, 2016.
6. Sambasivam pillai T.V., (1931), Tamil-English dictionary of medicine, chemistry, botany and allied sciences, the research Institute of Siddhar's science, mount road
7. Uththamanarayan K.S., (2013), Siddhar Aruvai Maruthuvam, Inthiya Maruthuvam-Homeopathi Thurai, Chaennai-600106
8. Venkatrajan S., (2007), Sarabendra Vaithiya Muraikal, Viranam Karappan roga sikithcahi, saraswathy mahal noolakam, Thankavoor.
9. Hakkim Mohammad Abdullah Sahib, (2020) Siddha Anuboga vaithiya navanitha thirattu, Printed by Va.U.Se. Noolakam.
10. Kumar A. R., Muthukumar N. J., & Faridha A. (2019). Neermulli kudineer – A classical polyherbal decoction in Siddha system of medicine. *Research Journal of Pharmacy and Technology*, 12(1), 445-460. <https://doi.org/10.5958/0974-360X.2019.00081.7>
11. Bobade A.A., Thatte C.V., & Tijare R.B. (2022). *Trichosanthes cucumerina*: A perspective on various medicinal uses or activities. *GSC Biological and Pharmaceutical Sciences*, 20(3), 141-147.
12. Witkowska K., Paczkowska-Walendowska M., Garbiec E., & Cielecka-Piontek J. (2024). Topical Application of *Centella asiatica* in Wound Healing: Recent Insights into Mechanisms and Clinical Efficacy. *Pharmaceutics*, 16(10), 1252. <https://doi.org/10.3390/pharmaceutics16101252>
13. Sakshi B., Shailza B., Kalpana Y., Pankaj Y., Pooja Y., Deepak J. and Ambika., (2024), "Antidiabetic Properties of *Chandraprabha Vati*", *AYUSHDHARA*. India, 11(5), pp. 136-145. doi: 10.47070/ayushdhara.v11i5. 1712.

14. Wanjari M.M., Mishra S., Dey Y.N., Sharma D., Gaidhani S.N., & Jadhav A.D. (2016). Antidiabetic activity of *Chandraprabha vati* - A classical Ayurvedic formulation. *Journal of Ayurveda and integrative medicine*, 7(3), 144–150. <https://doi.org/10.1016/j.jaim.2016.08.010>.
15. Weerasekera K.R., Dhammarathana I., Tissera A.H.M., Ariyawansa H.A.S. and Ratnasooriya W.D. (2015). Anti-inflammatory activity of an ayurvedic herbo-mineral formulation: *Chandraprabha vati*. *International Journal of Recent Advances in Multidisciplinary Research*, 2(6), 471-475.
16. Ayurvedic treatment for diabetic foot ulcer. Pristyn Care. Retrieved January 22, (2025), from <https://www.pristyncare.com/blog/ayurvedic-treatment-diabetic-foot-ulcer-pc0441/#>
17. Singh B., Gupta V., Bansal P., Kumar D., & Krishna C.M. (2011). Pharmacological potential of polyherbal formulation, sudarshan churna—a review. *International Journal of Ayurvedic Medicine*, 2(2), 52-61.
18. Tambekar D.H., Dahikar S.B., & Lahare M. D. (2009). Antibacterial potentials of some herbal preparations available in India. *Research Journal of Medicine and Medical Sciences*, 4(2), 224–227.
19. Bhargava P., Shukla K., Pandey R., Shukla S., & Jain S. (2008). Evaluation of Antimicrobial Potential of *Sudarshan Churna*: A Polyherbal Formulation. *Iranian Journal of Pharmacology and Therapeutics*, 7(2), 185–187.
20. Singh B., Kumar D., Jindal N., Gupta V., & Bansal P. (2014). In-vitro evaluation of antimicrobial potential of Ayurvedic poly-herbal formulation: *Sudarshan churna*. *World Journal of Pharmaceutical Research*, 3(2), 2684–2690.
21. Chandrasiri S.H.K.D., Jayatilaka K.A.P. W., & Premakumara G.A.S. (2020). Acute and Subchronic Oral Safety Profiles of the Sudarshana Suspension: A Novel Ayurvedic Preparation. *Journal of Toxicology*, 2020.
22. Rani S., Sharma U., Mitra S., Chandra M., & Sharma K. V. (2022). A critical review on *Sudarshan churna*. *International Journal of Research in Ayurveda and Pharmacy*, 13(5), 128–132.
23. Gill D., & Mahto R.R. (2019). Management of Diabetes Mellitus (Type with Anti Diabetic Ayurvedic Medicine – A Case Report. *International Journal of Ayurveda and Pharma Research*, 7(8), 33–37.
24. Rohini P. & Panagoda G.J. (2020). Preliminary in vitro study of antimicrobial activity of traditional mouthwash preparations. *Journal of, Traditional Medicine*, 45(3), 123-130. <https://doi.org/10.1234/jtm.2020.04503>